Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 67.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 24,674 shares of the biopharmaceutical company’s stock after purchasing an additional 9,908 shares during the quarter. Regeneron Pharmaceuticals makes up approximately 1.6% of China Universal Asset Management Co. Ltd.’s portfolio, making the stock its 12th largest position. China Universal Asset Management Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $17,576,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Mizuho Securities USA LLC grew its stake in shares of Regeneron Pharmaceuticals by 625.5% in the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after purchasing an additional 51,162 shares during the period. Principal Financial Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Simplify Asset Management Inc. raised its holdings in Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after purchasing an additional 3,231 shares during the period. Catalytic Wealth RIA LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $1,334,000. Finally, Daiwa Securities Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 12.3% during the 3rd quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company’s stock worth $21,428,000 after acquiring an additional 2,234 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $672.98 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The company has a 50 day moving average of $720.81 and a 200 day moving average of $924.07. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market cap of $73.95 billion, a P/E ratio of 16.65, a PEG ratio of 1.62 and a beta of 0.10.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price for the company. Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Evercore ISI decreased their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Finally, Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.